Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.
Also called NCT05303857
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 107 participants
- Registry
-
NCT05303857
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany
- Registry status
- Completed
Technical summary
Registry record NCT05303857. Randomized; triple masking; primary purpose treatment. Start 2022-03-03 (actual); primary completion 2023-12-15 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes
- Acronym
- SEMA
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Semaglutide Pen Injector
- Intervention (Drug)
- Placebo
- Lead sponsor
- University of Erlangen-Nürnberg Medical School
Record details
- Record id
cardio:ct-nct05303857- Content hash
d511ca0b89b0c39460a08e71b116edf2acaf26a266ea0894df671f6606a00ba8